Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Personalis, Inc.
< Previous
1
2
3
4
5
Next >
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis and Tempus Announce Expanded Collaboration
August 16, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
July 31, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Second Quarter 2024 Financial Results
July 24, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
June 18, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
June 13, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
June 04, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
May 31, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
May 22, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports First Quarter 2024 Financial Results
May 08, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 28, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
March 26, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 19, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at Upcoming Investor Conferences
January 31, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
January 30, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
January 16, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
January 05, 2024
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
December 04, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
November 28, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
October 26, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Third Quarter 2023 Financial Results
October 24, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
October 21, 2023
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today